CSIMarket
 
Vor Biopharma Inc   (VOR)
Other Ticker:  
 
 
Price: $1.9300 $0.09 4.607%
Day's High: $1.9529 Week Perf: -8.1 %
Day's Low: $ 1.87 30 Day Perf: -6.76 %
Volume (M): 355 52 Wk High: $ 6.18
Volume (M$): $ 686 52 Wk Avg: $3.02
Open: $1.89 52 Wk Low: $1.62



 Market Capitalization (Millions $) 130
 Shares Outstanding (Millions) 68
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -116
 Cash Flow (TTM) (Millions $) -16
 Capital Exp. (TTM) (Millions $) 1

Vor Biopharma Inc
Vor Biopharma Inc is a clinical-stage cell therapy company that is focused on developing and commercializing engineered hematopoietic stem cell (eHSC) therapies for the treatment of cancer. The company was founded in 2018 and is based in Cambridge, Massachusetts.

Vor Biopharma's eHSC therapies are designed to selectively target and eliminate cancer cells while preserving healthy cells. This unique approach involves modifying a patient's own stem cells to express chimeric antigen receptors (CARs) that specifically recognize and attack cancer cells. By harnessing the power of the immune system, Vor Biopharma aims to provide more effective and less toxic treatments for patients with various types of cancer.

The company's lead product candidate, VOR33, is being investigated for the treatment of acute myeloid leukemia (AML). VOR33 is designed to selectively target CD33, a protein that is highly expressed on leukemia cells. Vor Biopharma is also exploring the potential of its eHSC platform for the development of therapies for other hematologic malignancies and solid tumors.

Vor Biopharma has established collaborations with leading academic institutions and industry partners to support its research and development efforts. The company has also raised significant funding to advance its pipeline and accelerate the development of its eHSC therapies.

Overall, Vor Biopharma is dedicated to revolutionizing cancer treatment by leveraging the power of engineered stem cells to provide safe and effective therapies for patients in need.


   Company Address: 100 Cambridgepark Drive Cambridge 2140 MA
   Company Phone Number: 655-6580   Stock Exchange / Ticker: NASDAQ VOR
   VOR is expected to report next financial results on March 22, 2024.


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Shares

Vor Bio's Inducement Grants Fuel Talent Acquisition and Drive Positive Growth in Share Price

Published Tue, Mar 5 2024 9:01 PM UTC

Vor Bio's Inducement Grants Drive Talent Acquisition and Reflect Positive Growth
CAMBRIDGE, Mass., March 05, 2024 - Vor Bio (Nasdaq: VOR), a leading clinical-stage cell and genome engineering company, has recently disclosed its most recent inducement grants under Nasdaq Listing Rule 5635(c)(4). This announcement comes as part of the company's ongoing efforts to attract ...

Stock Market Announcement

Vor Bio Boosts Employee Retention with Inducement Grants: Impact on Company Shares Assessed

Published Fri, Feb 2 2024 9:01 PM UTC



In a recent press release, Vor Bio, a clinical-stage cell and genome engineering company, announced the granting of stock options and restricted stock units (RSUs) to five newly hired employees. These inducement grants were made in accordance with Nasdaq Listing Rule 5635(c)(4) and the company's Inducement Plan. This article will outline the key facts of the press ...

Clinical Study

Vor Bio Embarks on Historic Journey, administers first dose of VCAR33 (ALLO) in Clinical Trial

Published Wed, Jan 17 2024 9:01 PM UTC

Clinical-stage cell and genome engineering firm Vor Bio proudly announced on January 17, 2024, that it has accomplished a crucial first step towards developing a new therapy for acute myeloid leukemia (AML) by dosing the first patient in its Phase 1/2 clinical trial of VCAR33 (ALLO), dubbed VBP301. This marks the first time in human history that this innovative cellular ther...

Shares

Vor Bio Employs Inducement Grants to Foster Growth in Turbulent Market

Published Fri, Dec 1 2023 9:01 PM UTC



Vor Bio, a clinical-stage cell and genome engineering company, has recently made a significant announcement regarding the grant of stock options and restricted stock units (RSUs) to four newly hired employees. This move, made under the Nasdaq Listing Rule 5635(c)(4) and the Vor Biopharma Inc. 2023 Inducement Plan, aims to attract top talent by offering enticing inc...

Vor Biopharma Inc

Vor Biopharma Inc Reports Significant Operating Shortfall in Q3 2023

Vor Biopharma Inc Faces Operating Shortfall in Q3 of 2023
As the fiscal earnings cycle for the period of July to September 2023 resumes, several corporations have started announcing their financial results. Among these announcements are various constituents of the Biotechnology & Pharmaceuticals sector. Today, Vor Biopharma Inc (VOR), a clinical-stage cell and genome engineering company, reported an operating shortfall of $-35.316 million for the third quarter of 2023. This represents a significant decline from the operating shortfall of $-24.101 million recorded in the same quarter of the previous year.
The financial performance of Vor Biopharma Inc has raised concerns among analysts, who are now wondering if the company can start showing improvements in its top-line revenues. In an effort to find new sources of revenue, the Chief Financial Officer (CFO) is currently exploring various financial plans.






 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com